Generic Name and Formulations:
Sulfacetamide sodium 10%; oph. soln; contains benzalkonium chloride.
- Centripetal Propagation of Vasoconstriction Indicates Severity of Reversible Cerebral Vasoconstriction Syndrome
- Cholinergic Activity Greater in LRRK2 Mutation Carriers Regardless of Parkinson's Diagnosis
- Atypical FDG-PET Patterns Predict Higher Dementia Risk in Parkinson Disease
- Hypertension: Beta-Blocker Pharmacokinetics
- Hypertension Treatments: ACE Inhibitors
- Combination Hypertension Treatments
Indications for BLEPH-10:
Susceptible infections of conjunctiva and cornea. Adjunct in trachoma.
Adults and Children:
<2months: not recommended. ≥2months: Conjunctivitis: 1–2 drops every 2–3 hrs during the day (less often at night). Trachoma: 2 drops every 2 hrs w. systemic therapy.
Purulent exudates may inactivate drug. Discontinue if hypersensitivity or rash occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Incompatible with silver-containing preparations. May be antagonized by PABA.
Local irritation, stinging, burning, superinfection, sensitization.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies